Business Briefing: F.D.A. Clears Cheaper Version of Johnson & Johnson Biologic
Saturday, April 9, 2016 - 07:00
in Psychology & Sociology
Federal officials have approved a cheaper version of Johnson & Johnson’s blockbuster drug Remicade, a biotech medicine for inflammatory diseases.